The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF).

Pulmonary Fibrosis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP)

BMC Pulmonary Medicine ◽

10.1186/s12890-019-0830-x ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 7

Author(s):

Jean-Marc Naccache ◽

Melissa Montil ◽

Jacques Cadranel ◽

Marine Cachanado ◽

Vincent Cottin ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Acute Exacerbation ◽

Study Protocol ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3379814 ◽

2019 ◽

Author(s):

Luca Richeldi ◽

Evans R. Fernández Pérez ◽

Ulrich Costabel ◽

Carlo Albera ◽

David J. Lederer ◽

...

Keyword(s):

Growth Factor ◽

Connective Tissue ◽

Pulmonary Fibrosis ◽

Controlled Trial ◽

Tissue Growth ◽

Double Blind ◽

Double Blind Placebo ◽

Factor Therapy ◽

Growth Factor Therapy

S91 A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis

Thorax ◽

10.1136/thoraxjnl-2015-207770.97 ◽

2015 ◽

Vol 70 (Suppl 3) ◽

pp. A52.1-A52 ◽

Cited By ~ 1

Author(s):

I Satia ◽

H Badri ◽

R Dockry ◽

N Chaudhuri ◽

G Brown ◽

...

Keyword(s):

Single Dose ◽

Pulmonary Fibrosis ◽

Crossover Study ◽

Adult Patients ◽

Double Blind ◽

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(16)30044-3 ◽

2016 ◽

Vol 4 (6) ◽

pp. 445-453 ◽

Cited By ~ 67

Author(s):

Jürgen Behr ◽

Elisabeth Bendstrup ◽

Bruno Crestani ◽

Andreas Günther ◽

Horst Olschewski ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Combination Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Advances in Therapy ◽

10.1007/s12325-019-01052-y ◽

2019 ◽

Vol 36 (10) ◽

pp. 2910-2926 ◽

Cited By ~ 4

Author(s):

Marilyn K. Glassberg ◽

Steven D. Nathan ◽

Chin-Yu Lin ◽

Elizabeth A. Morgenthien ◽

John L. Stauffer ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Phase Iii ◽

Cardiovascular Risks ◽

Clinical Events ◽

Faculty Opinions recommendation of Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718270310.793490583 ◽

2014 ◽

Author(s):

Toby Maher

Keyword(s):

Pulmonary Fibrosis ◽

Controlled Trial ◽

Double Blind ◽

Fatigue in patients with idiopathic pulmonary fibrosis (IPF) from the pooled pirfenidone (PFD) Phase III trials

10.1183/1393003.congress-2017.pa4875 ◽

2017 ◽

Cited By ~ 1

Author(s):

Ulrich Costabel ◽

Carlo Albera ◽

Marlies S. Wijsenbeek ◽

Joao A. de Andrade ◽

Wendi R. Mason ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Phase Iii ◽

T1402 Efficacy of 12-Week Treatment with Prucalopride (Resolor®) in Patients with Chronic Constipation: Combined Results of Three Identical Randomized, Double-Blind, Placebo-Controlled Phase III Trials

Gastroenterology ◽

10.1016/s0016-5085(08)62556-1 ◽

2008 ◽

Vol 134 (4) ◽

pp. A-548 ◽

Cited By ~ 6

Author(s):

Michael Camilleri ◽

Renate Specht Gryp ◽

Rene Kerstens ◽

Lieve Vandeplassche

Keyword(s):

Chronic Constipation ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00354-4 ◽

2021 ◽

Author(s):

Jean-Marc Naccache ◽

Stéphane Jouneau ◽

Morgane Didier ◽

Raphaël Borie ◽

Marine Cachanado ◽

...

Keyword(s):

Pulmonary Fibrosis ◽

Acute Exacerbation ◽

Phase 3 ◽

Double Blind ◽

Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2)

Gastroenterology ◽

10.1016/s0016-5085(14)63540-x ◽

2014 ◽

Vol 146 (5) ◽

pp. S-974 ◽

Cited By ~ 4

Author(s):

Donald M. Jensen ◽

Graham Foster ◽

Peter Ferenci ◽

Curtis Cooper ◽

Douglas T. Dieterich ◽

...

Keyword(s):

Pegylated Interferon ◽

Pooled Analysis ◽

Interferon Alfa ◽

Phase Iii ◽

Genotype 1 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Trials ◽

Treatment Naïve ◽

Pegylated Interferon Alfa